URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Sven Dethlefs Biography and Net Worth

EVP of Teva Pharmaceutical Industries

Sven Dethlefs (Ph.D) became Executive Vice President, North America Commercial in August 2021, leading all commercial activities of Teva USA and Teva Canada’s Generic and Specialty businesses.

Headquartered in Parsippany, NJ, Teva USA’s generic medicines saved the US healthcare system $28.8B in 2020 alone, and in the US, 10 prescriptions are filled with a Teva product every second. Teva USA maintains leadership positions with broad generic and specialty portfolios across varying therapeutic conditions, including movement disorders, mental health and respiratory. Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for over 50 years, with currently more than 179,000 prescriptions filled each day.

Sven Dethlefs has been part of Teva’s Executive Management team since 2017, where he served as Executive Vice President, Global Marketing and Portfolio, assuming responsibility for International Markets, Commercial in 2021. He also held leadership roles in Teva’s Global Specialty business, Commercial European business and Global Operations (TGO). Sven has played an integral role in optimizing Teva's vast global portfolio, in developing the R&D pipeline strategy, and leading global marketing teams.

Sven joined Teva as General Manager, Teva Germany in 2008. Prior to joining Teva, he served for over eleven years as a partner at McKinsey & Company.

Sven received his Ph.D. in biochemistry from the FU Berlin/Pasteur Institute Paris.

What is Sven Dethlefs' net worth?: The estimated net worth of Sven Dethlefs is at least $4.94 million as of March 6th, 2023. Dr. Dethlefs owns 223,447 shares of Teva Pharmaceutical Industries stock worth more than $4,935,944 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Dethlefs may own. Learn More about Sven Dethlefs' net worth.
How do I contact Sven Dethlefs?: The corporate mailing address for Dr. Dethlefs and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Sven Dethlefs' contact information.
Has Sven Dethlefs been buying or selling shares of Teva Pharmaceutical Industries?: Sven Dethlefs has not been actively trading shares of Teva Pharmaceutical Industries during the last quarter. Most recently, Sven Dethlefs sold 19,355 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $9.93, for a transaction totalling $192,195.15. Following the completion of the sale, the executive vice president now directly owns 223,447 shares of the company's stock, valued at $2,218,828.71. Learn More on Sven Dethlefs' trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 984,382 shares worth more than $15,236,840.56. The most recent insider tranaction occured on November, 20th when EVP Christine Fox sold 19,388 shares worth more than $327,075.56. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/20/2024.

Sven Dethlefs Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Sell	19,355	$9.93	$192,195.15	223,447
2/28/2023	Sell	59,655	$9.89	$589,987.95	165,381
2/9/2022	Sell	4,138	$9.06	$37,490.28
3/18/2019	Sell	632	$16.63	$10,510.16	9,781
3/12/2019	Sell	647	$15.67	$10,138.49	9,249
3/4/2019	Sell	606	$16.88	$10,229.28	8,664
9/18/2018	Sell	625	$23.71	$14,818.75	7,890
8/3/2018	Buy	2,000	$21.92	$43,840.00	6,445
3/19/2018	Sell	571	$17.88	$10,209.48	5,016

Sven Dethlefs Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $22.09

$21.11

$22.17

50 Day Range

MA: $17.79

$16.44

$22.09

2 Week Range

Now: $22.09

$10.34

$22.17

Volume

12,760,563 shs

Average Volume

9,444,773 shs

Market Capitalization

$25.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79